Your shopping cart is currently empty

BTK-IN-17 is a selective, orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an inhibition concentration (IC50) value of 13.7 nM. It effectively reduces the expression of phosphorylated BTK at Tyrosine 223 (p-BTK Y223) and phosphorylated Phospholipase C Gamma 2 at Tyrosine 1217 (p-PLCγ2 Y1217), demonstrating anti-inflammatory properties.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,120 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $2,780 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $3,700 | 8-10 weeks | 8-10 weeks |
| Description | BTK-IN-17 is a selective, orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an inhibition concentration (IC50) value of 13.7 nM. It effectively reduces the expression of phosphorylated BTK at Tyrosine 223 (p-BTK Y223) and phosphorylated Phospholipase C Gamma 2 at Tyrosine 1217 (p-PLCγ2 Y1217), demonstrating anti-inflammatory properties. |
| Molecular Weight | 465.51 |
| Formula | C26H23N7O2 |
| Smiles | C=CC(=O)N1CC[C@H](C1)N2C3=C4C(=CN=C4NC=N3)C(=N2)NC5=CC=C(C=C5)OC6=CC=CC=C6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.